Kyverna Therapeutics (NASDAQ:KYTX) Issues Earnings Results, Beats Expectations By $0.03 EPS

Kyverna Therapeutics (NASDAQ:KYTX) posted its earnings results on Monday. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.03, Briefing.com reports.

Kyverna Therapeutics Stock Down 1.6 %

Shares of KYTX stock traded down $0.11 during mid-day trading on Wednesday, hitting $6.89. 8,794 shares of the company’s stock were exchanged, compared to its average volume of 519,629. Kyverna Therapeutics has a fifty-two week low of $6.30 and a fifty-two week high of $35.06. The company has a 50-day simple moving average of $9.05.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on KYTX shares. JPMorgan Chase & Co. reduced their target price on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. HC Wainwright restated a “neutral” rating and issued a $8.00 price objective on shares of Kyverna Therapeutics in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.60.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.